Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of ABM-125 in poorly controlled asthmatics susceptible to exacerbations following naturally acquired rhinovirus infection

Next Previous
Trial Profile

A phase III study of ABM-125 in poorly controlled asthmatics susceptible to exacerbations following naturally acquired rhinovirus infection

Planning
Phase of Trial: Phase III

Latest Information Update: 23 May 2017

At a glance

  • Drugs ABM 125 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top